Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Research & Development (2020 - 2025)

Bolt Biotherapeutics' Research & Development history spans 6 years, with the latest figure at $6.5 million for Q3 2025.

  • For Q3 2025, Research & Development fell 52.59% year-over-year to $6.5 million; the TTM value through Sep 2025 reached $35.3 million, down 43.18%, while the annual FY2024 figure was $57.5 million, 6.62% down from the prior year.
  • Research & Development for Q3 2025 was $6.5 million at Bolt Biotherapeutics, down from $7.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $22.5 million in Q4 2021 and bottomed at $6.5 million in Q3 2025.
  • The 5-year median for Research & Development is $15.6 million (2023), against an average of $15.3 million.
  • The largest annual shift saw Research & Development skyrocketed 115.0% in 2021 before it plummeted 52.59% in 2025.
  • A 5-year view of Research & Development shows it stood at $22.5 million in 2021, then decreased by 25.08% to $16.8 million in 2022, then decreased by 3.1% to $16.3 million in 2023, then dropped by 28.18% to $11.7 million in 2024, then plummeted by 44.25% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Research & Development are $6.5 million (Q3 2025), $7.5 million (Q2 2025), and $9.5 million (Q1 2025).